High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk Acute Myeloid Leukemia (AML)

References

• Wierzbowska A, Robak T, Pluta A, . Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group. Eur J Haematol 2008;80: 115–126.
   PubMed Web of Science ®Google Scholar
• van der Holt B, Lowenberg B, Burnett AK, . The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 2005;106:2646–2654.
   PubMed Web of Science ®Google Scholar
• Rowe JM, Neuberg D, Friedenberg W, . A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004;103:479–485.
   PubMed Web of Science ®Google Scholar
• Preisler HD, Venugopal P, Gregory SA, . Poor prognosis acute myelogenous leukemia: 1 - response to treatment with high dose cytarabine/mitoxantrone/ethyol@(Amifostine). Leuk Res 2000;24: 671–680.
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Suciu S, Archimbaud E, . Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy-the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol 1998;16:872–881.
   PubMed Web of Science ®Google Scholar
• Goldstone AH, Burnett AK, Wheatley K, . Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 2001;98:1302–1311.
   PubMed Web of Science ®Google Scholar
• Faderl S, Ravandi F, Huang X, . A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008;112:1638–1645.
   PubMed Web of Science ®Google Scholar
• Estey EH, Thall PF, Giles FJ, . Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood 2002;99:4343–4349.
   PubMed Web of Science ®Google Scholar
• Buchner T, Hiddemann W, Wormann B, . Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood 1999;93:4116–4124.
   PubMed Web of Science ®Google Scholar
• Arlin Z, Case DC, Jr., Moore J, . Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group. Leukemia 1990;4:177–183.
   PubMed Web of Science ®Google Scholar
• Anderson JE, Kopecky KJ, Willman CL, . Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. Blood 2002;100:3869–3876.
   PubMed Web of Science ®Google Scholar
• Daenen S, Lowenberg B, Sonneveld P, . Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine. Dutch Hematology-Oncology Working Group for Adults (HOVON). Leukemia 1994;8:6–10.
   PubMed Web of Science ®Google Scholar
• Ho AD, Lipp T, Ehninger G, . Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia—an active and well-tolerated regimen. J Clin Oncol 1988;6:213–217.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Estey EH, Keating MJ. Treatment of therapy-related leukemia and myelodysplastic syndrome. Hematol Oncol Clin North Am 1993;7:81–107.
   PubMed Web of Science ®Google Scholar
• Takeyama K, Seto M, Uike N, . Therapy-related leukemia and myelodysplastic syndrome: a large-scale Japanese study of clinical and cytogenetic features as well as prognostic factors. Int J Hematol 2000; 71:144–152.
   PubMed Web of Science ®Google Scholar
• Walter RB, Kantarjian HM, Huang X, . Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study. J Clin Oncol 2010;28:1766–1771.
   PubMed Web of Science ®Google Scholar
• Raza A, Preisler HD, Day R, . Direct relationship between remission duration in acute myeloid leukemia and cell cycle kinetics: a leukemia intergroup study. Blood 1990;76:2191–2197.
   PubMed Web of Science ®Google Scholar
• Quinones VW. Recruitment of acute myeloid leukemia cells into cell cycle using timed sequential high dose cytarabine and mitoxantrone at first relapse. Blood 1996: 3147a.
   Google Scholar
• Preisler HD, Venugopal P, Gregory SA, . High remission rate in acute myeloblastic leukemia with only two days of chemotherapy. Leuk Lymphoma 2001;41:333–336.
   PubMed Web of Science ®Google Scholar
• Grimwade D, Walker H, Oliver F, . The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92:2322–2333.
   PubMed Web of Science ®Google Scholar
• Slovak ML, Kopecky KJ, Cassileth PA, . Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000;96:4075–4083.
   PubMed Web of Science ®Google Scholar
• Extermann M. Measuring comorbidity in older cancer patients. Eur J Cancer 2000;36:453–471.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Khatcheressian J, Lyman GH, . 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24: 3187–3205.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kopecky KJ, . Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21:4642–4649.
   PubMed Web of Science ®Google Scholar
• Baer MR, George SL, Dodge RK, . Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 2002;100:1224–1232.
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Lee SJ, Advani R, . Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol 2004;22: 1078–1086.
   PubMed Web of Science ®Google Scholar
• Kolitz JE, George SL, Marcucci G, . P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood 2010;116:1413–1421.
   PubMed Web of Science ®Google Scholar
• Koreth J, Schlenk R, Kopecky KJ, . Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009;301:2349–2361.
   PubMed Web of Science ®Google Scholar
• Yanada M, Matsuo K, Emi N, . Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer 2005;103:1652–1658.
   PubMed Web of Science ®Google Scholar
• Sierra J, Storer B, Hansen JA, . Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. Blood 1997;89:4226–4235.
   PubMed Web of Science ®Google Scholar
• Wong R, Shahjahan M, Wang X, . Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant 2005;1:108–114.
   Web of Science ®Google Scholar
• Duval M, Klein JP, He W, . Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol 2010;28:3730–3738.
   PubMed Web of Science ®Google Scholar
• Cashen AF, Schiller GJ, O'Donnell MR, . Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 2010;28:556–561.
   PubMed Web of Science ®Google Scholar
• Blum W, Garzon R, Klisovic RB, . Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A 2010;107:7473–7478.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Erba HP, Claxton D, . Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol 2010;28:549–555.
   PubMed Web of Science ®Google Scholar
• Kayser S, Dohner K, Krauter J, . The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 2011;117:2137–2145.
   PubMed Web of Science ®Google Scholar
• Godley LA, Njiaju UO, Green M, . Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. Leuk Lymphoma 2010;51:995–1006.
   PubMed Web of Science ®Google Scholar
• Brown RA, Herzig RH, Wolff SN, . High-dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hematologic malignancy. Blood 1990;76:473–479.
   PubMed Web of Science ®Google Scholar
• Cortes J, Estey E, O'Brien S, . High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia. Cancer 2001;92: 7–14.
   PubMed Web of Science ®Google Scholar
• Liu Yin JA, Wheatley K, Rees JK, . Comparison of ‘sequential’ versus ‘standard’ chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial. Br J Haematol 2001;113:713–726.
   PubMed Web of Science ®Google Scholar
• Stone RM, Moser B, Sanford B, . High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902. Leuk Res 2011;35(3):329–333.
   PubMed Web of Science ®Google Scholar